Search for: "HCA, Inc." Results 41 - 60 of 152
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
31 Jan 2018, 2:10 pm by Hunton & Williams LLP
” ERSP Targets Misleading Advertising Tied to Dietary, Weight-Loss Supplement The Electronic Retailing Self-Regulation Program (“ERSP”) targeted Mayfair Industries, Inc. [read post]
13 Aug 2017, 12:54 am by Mark Summerfield
  This suggests to me that the Patent Office is continuing to grapple with the principles of patent-eligibility set out in Research Affiliates, RPL Central, and D’Arcy v Myriad Genetics Inc [2015] HCA 35, and that applicants therefore still cannot expect predictable or consistent outcomes as examiners endeavour to apply these principles on a case-by-case basis. [read post]
12 Apr 2017, 4:47 pm by Stephen Page
Recently I presented at the seventh annual Family Law Forum run by Legalwise in Brisbane about third party property settlement issues. [read post]
29 Jul 2016, 11:57 pm by Mark Summerfield
  These are difficult cases at the very frontiers of patent-eligibility under the law as it stands following the Full Federal Court judgments in Research Affiliates LLC v Commissioner of Patents [2014] FCAFC 150 and Commissioner of Patents v RPL Central Pty Ltd [2015] FCAFC 177, along with the High Court judgment in D'Arcy v Myriad Genetics Inc [2015] HCA 35. [read post]
30 Jun 2016, 9:58 am by Steven Koprince
Supreme Court’s decision in Kingdomware Technologies, Inc. v. [read post]
15 Feb 2016, 5:24 am by Patrick A. Malone
” The participants include:  American Express,  American Water, BNSF Railway,  Brunswick, Caterpillar, Coca-Cola, E.I. du Pont de Nemours, HCA Inc, Hartford Financial Services, IBM,  Ingersoll Rand, International Paper, Lincoln Financial, Macy’s,  Marriott International, NextEra Energy, Pitney Bowes, Shell Oil,  Verizon Communications, and Weyerhaeuser. [read post]
5 Dec 2015, 11:59 pm by Mark Summerfield
  These provisions apply particularly to regulated products, including  pharmaceuticals and biologics (a.k.a biopharmaceuticals).In this article I will look at three specific aspects of the TPP:the obligation to provide for adjustment of the patent term to compensate for ‘unreasonable delays’ in the grant of a patent, about which I expect Australia to do nothing; the obligation to provide for extensions of the term of patents relating to pharmaceutical products as compensation… [read post]
13 Nov 2015, 9:00 am
., Board Certified by The Florida Bar in Health Law Just days after settling with the US Department of Justice (DOJ) agreeing to pay $16 million to resolve allegations of False Claims Act (FCA) violations, HCA Holdings, Inc. [read post]
13 Nov 2015, 9:00 am
., Board Certified by The Florida Bar in Health Law Just days after settling with the US Department of Justice (DOJ) agreeing to pay $16 million to resolve allegations of False Claims Act (FCA) violations, HCA Holdings, Inc. [read post]
13 Nov 2015, 9:00 am
., Board Certified by The Florida Bar in Health Law Just days after settling with the US Department of Justice (DOJ) agreeing to pay $16 million to resolve allegations of False Claims Act (FCA) violations, HCA Holdings, Inc. [read post]